Skip to main content
. 2012 May 25;7(5):e37787. doi: 10.1371/journal.pone.0037787

Figure 6. Inhibition of Slc10a2 reduces mRNA levels of enzymes in fatty acid and glucose metabolism.

Figure 6

Ob/ob mice were treated with the specific Slc10a2 protein inhibitor, AZD7806 or control vehicle (Controls) (see experimental procedures). (A) Hepatic mRNA levels of Srebp1c, and its target genes acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas) and stearoyl-CoA desaturase 1 (Scd1). (B) Hepatic mRNA levels of glucokinase (Gk), pyruvate kinase (Lpk), glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (Pepck) mRNA levels of the control vehicle treated animals are normalized to 1. Data are represented as mean ± standard error (SEM). Significances of differences between groups was tested by Student’s t test, a p-value <0.05 is denoted *.